Investigational medication for pediatric patients with Autism, Asperger’s disorder, or Pervasive developmental disorder.

New studies evaluating the safety and tolerability of an extended release formulation¬† of Memantine in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

  • Approximately one year study duration
  • Ages 6-12 years
  • Must have an IQ of at least 50
  • There must be a consistant caregiver to attend study visits with the child